Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
The incidence of bladder cancer is on the rise due to aging populations, necessitating increased demand for diagnostics and therapies. Technological advancements and awareness campaigns are playing important roles in early detection, thereby augmenting the market. With growing healthcare expenditure, there's a significant push towards research and personalized treatment options, promising better outcomes for patients. Additionally, expansion into emerging markets is fostering demand for advanced solutions, highlighting a global need for improved bladder cancer management strategies. New York, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Bladder Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain Bladder cancer, marked by abnormal cell growth in the bladder lining, presents a global health concern. The incidence of bladder cancer is on the rise due to aging populations, necessitating increased demand
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024Business Wire
- ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCBusiness Wire
- Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.MarketBeat
- UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]Seeking Alpha
URGN
Earnings
- 8/13/24 - Miss
URGN
Sec Filings
- 10/24/24 - Form SC
- 10/9/24 - Form 4
- 10/9/24 - Form 3
- URGN's page on the SEC website